RxDoctor Payments Data

Alexandra Lewis

Physician Assistant · Lantana, FLNPI 1194719609

Payments from drug & device makers

$2,300in general payments, 2019–2025

Across 93 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$329
  • AstraZeneca$303
  • Novo Nordisk$190
  • Mayne Pharma Commercial LLC$170
  • Astellas Pharma US Inc$134
  • Pfizer$132
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,13893%
  • Education$1627%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,300 in reported general payments places this provider in the 75th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$20,640
Medicare patients
124
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$29,033
EliquisApixaban23$26,288
XareltoRivaroxaban16$26,219
JardianceEmpagliflozin16$24,702
TrulicityDulaglutide25$21,718
Valsartan146$3,363
Levothyroxine Sodium328$3,205
LantusInsulin Glargine,hum.Rec.Anlog12$2,229
Rosuvastatin Calcium217$1,793
Atorvastatin Calcium221$1,759
Fluticasone Propionate120$1,643
Losartan Potassium201$1,514
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,485
Albuterol Sulfate HfaAlbuterol Sulfate36$1,423
Liothyronine Sodium37$1,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$190$29,03324 claims
PfizerEliquis$132$26,28823 claims
Johnson & JohnsonXarelto$72$26,21916 claims
Boehringer IngelheimJardiance$329$24,70216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Lantana

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →